Shijiazhuang Yiling Pharmaceutical News

Eling Pharmaceutical (002603) 2024 Third Quarterly Report Review: After the pain of adjustment, looking forward to fixing the inflection point

Huachuang SecuritiesNov 4 18:17

Eling Pharmaceutical (002603): Short-term performance is under pressure, academics lead long-term development

Debang SecuritiesNov 1 14:17

Eling Pharmaceutical (002603) Depth: Complexity theory guides the direction of traditional Chinese medicine innovation Lianhua series restarts new growth momentum

swhy ResearchSep 25 18:36

Eling Pharmaceutical (002603): Short-term performance is under pressure and is expected to recover in the second half of the year

Aug 29 16:21

Eling Pharmaceutical (002603): 24H1 respiratory sales are under pressure and evidence-based medical evidence continues to accumulate

Aug 28 19:46

Eling Pharmaceutical (002603): Non-respiratory products are growing steadily, and R&D results continue to show

May 14 15:46

Eling Pharmaceutical (002603): The R&D pipeline is rich and non-respiratory products are growing steadily

May 4 14:51

Eling Pharmaceutical (002603): Short-term performance is under pressure, and non-respiratory products are growing steadily

Apr 30 18:56

Eling Pharmaceutical (002603) Company Information Update Report: Short-term business performance is under pressure, innovative attributes help long-term development

Apr 30 00:00

Eling Pharmaceutical (002603): Performance is in line with expectations, go to the game lightly and start again

Apr 29 19:01

Eling Pharmaceutical (002603): Under pressure from 23 and 1Q24 results, it is expected to improve quarter by quarter

Apr 29 07:26

Eling Pharmaceutical (002603) 2023 Third Quarter Report Review: Short-term performance under pressure, R&D has been fruitful

Nov 2, 2023 07:42

Yiling Pharmaceutical (002603): Short-term performance under pressure, R&D pipeline enters the implementation period

Nov 2, 2023 00:00

Yiling Pharmaceutical (002603): Short-term performance under pressure, patent Chinese medicine research and development continues to advance

Oct 31, 2023 00:00

Yiling Pharmaceutical (002603): Short-term R&D work in the respiratory sector continues to advance under pressure

Oct 30, 2023 15:32

Eling Pharmaceutical (002603): Short-term performance under pressure, insisting on innovative drug research and development to tap endogenous growth potential

Oct 30, 2023 00:00

Eling Pharmaceutical (002603) 2023 Third Quarter Report Review Report: Steady growth in the first three quarters is optimistic about the company's long-term development

Oct 29, 2023 00:00

Eling Pharmaceutical (002603): Lianhua drags down the steady state of mind, and academics are welcoming results again

Oct 29, 2023 00:00

Eling Pharmaceutical (002603): COVID-19 performance continues to be digested, and innovative products are expected to continue to grow

Oct 29, 2023 00:00

Yiling Pharmaceutical (002603): Short-term performance under pressure, continuous implementation of innovative achievements

Oct 28, 2023 00:00